Reports and insights
PharmaFutures4: explores the growing challenge of reconciling unmet patient need with pharmaceutical R&D, in the context of changes in what society is willing to pay for and concerns among investors about the return on investment.
PharmaFutures3: Emerging Opportunities (2009) explores the link between sustainable pharmaceutical business models and global health outcomes in emerging markets.
PharmaFutures2: Prescription for Long-Term Value (2007) outlines the findings of a 12 month facilitated dialogue between leading industry executives and major institutional investors on how the sector can better deliver long-term value to shareholders and consumers.
PharmaFutures 1: A Long-Term Value Outlook (2004) presents the findings of the PharmaFutures scenario planning project. The report is sponsored by three major pension funds – ABP (Netherlands), the Ohio Public Employees Retirement System (OPERS, US), and the Universities’ Superannuation Scheme (USS, UK).
Comments
Innovation remains core to our success, ensuring we research and develop new medicines and vaccines which address unmet medical needs. The Shared Value report outlines how all stakeholders including industry, investors, governments and regulators can play their part in ensuring the appropriate balance between value for money and delivering fair rewards for innovation can be achieved.
Simon Jose, GSK